Skip to main content

Cost-effective reimbursement analysis for medical technologies in Europe

Procedure coding, payment mechanism, reimbursement tariffs, policy, and HTA considerations in 15 EU countries

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

2026 DRG tariffs published in France

On January 14, 2026, the Ministry of Health, Family, Autonomy and People with Disability published the Order setting DRG tariffs and tariffs for other packages and supplements for 2026. New tariffs are in force from January 1, 2026. The Agency for Technical Hospital Information (ATIH) also published the 2026 tariffs in Excel and other formats.

In 2026, specific higher tariffs are introduced for several procedures. One illustrative example is transrectal high-intensity focused ultrasound (HIFU) destruction of prostate lesions:

  • This financing mechanism was established by the recent update of the Benefit Order, which differentiated homogeneous groups of stays (GHS) within the DRG root 12C04 "Transurethral prostatectomy" based on the performance of HIFU destruction of prostate lesions;
  • When the procedure described with CCAM code JGND858 ("Destruction of prostate lesion by high-intensity focused ultrasound [HIFU], transrectally with ultrasound guidance") is performed, the hospital stay is allocated to one of the specific GHSs with higher tariffs;
  • For example, in the public sector, transrectal HIFU destruction of prostate lesions performed in hospital settings without complications will be reimbursed under GHS 8941 (€7,763) instead of GHS 4518 (€2,570);
  • Previously, the HIFU destruction of prostate lesions was covered under the Forfait Innovation scheme.

The 2026 Tariff Order also contains several updates in the field of organ perfusion technologies, including the implementation of a specific tariff for the utilization of cardiac graft perfusion machines within the Annual Grant for Transplants (Forfait Annuel Greffes, FAG).

See more details in French herehere, and here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.